SG11201600337PA - SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID - Google Patents
SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACIDInfo
- Publication number
- SG11201600337PA SG11201600337PA SG11201600337PA SG11201600337PA SG11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA SG 11201600337P A SG11201600337P A SG 11201600337PA
- Authority
- SG
- Singapore
- Prior art keywords
- self
- fatty acid
- emulsifying composition
- emulsifying
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dispersion Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013149662 | 2013-07-18 | ||
PCT/JP2014/069114 WO2015008848A1 (ja) | 2013-07-18 | 2014-07-17 | ω3脂肪酸の自己乳化組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201600337PA true SG11201600337PA (en) | 2016-02-26 |
Family
ID=52346290
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201800243XA SG10201800243XA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
SG11201600337PA SG11201600337PA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201800243XA SG10201800243XA (en) | 2013-07-18 | 2014-07-17 | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |
Country Status (12)
Country | Link |
---|---|
US (2) | US20160158184A1 (zh) |
EP (2) | EP3023099B1 (zh) |
JP (4) | JPWO2015008848A1 (zh) |
KR (1) | KR102275447B1 (zh) |
CN (4) | CN111939125A (zh) |
CA (1) | CA2918330C (zh) |
ES (1) | ES2841344T3 (zh) |
HK (1) | HK1222551A1 (zh) |
MY (1) | MY187003A (zh) |
PH (1) | PH12016500100B1 (zh) |
SG (2) | SG10201800243XA (zh) |
WO (1) | WO2015008848A1 (zh) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2334295T3 (en) | 2008-09-02 | 2017-10-09 | Amarin Pharmaceuticals Ie Ltd | PHARMACEUTICAL COMPOSITION COMPREHENSIVE EICOSAPENTAIC ACID AND NICOTIC ACID AND PROCEDURES FOR USING SAME |
AU2010241567B2 (en) | 2009-04-29 | 2013-10-31 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
WO2010127103A1 (en) | 2009-04-29 | 2010-11-04 | Amarin Pharma, Inc. | Stable pharmaceutical composition and methods of using same |
US8455472B2 (en) | 2009-06-15 | 2013-06-04 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101798670B1 (ko) | 2009-09-23 | 2017-11-16 | 아마린 코포레이션 피엘씨 | 오메가-3 지방산 및 스타틴의 히드록시-유도체를 포함하는 제약 조성물 및 그의 사용 방법 |
NZ727980A (en) | 2010-11-29 | 2018-08-31 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US20130131170A1 (en) | 2011-11-07 | 2013-05-23 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
RS61557B1 (sr) | 2012-06-29 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Postupci za smanjenje rizika od kardiovaskularnog događaja kod pacijenta na terapiji statinom primenom etil estra eikozapentaenske kiseline |
WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
CN107405326B (zh) * | 2015-01-21 | 2021-06-15 | 持田制药株式会社 | ω3脂肪酸的自乳化组合物 |
CN107427484A (zh) * | 2015-01-21 | 2017-12-01 | 持田制药株式会社 | ω3脂肪酸的自乳化组合物 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018054265A1 (zh) * | 2016-09-20 | 2018-03-29 | 张碧婷 | 亲水性脂类组合物的包装组合物,其制备及调配方法和应用 |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
WO2020068163A1 (en) | 2018-09-24 | 2020-04-02 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject |
KR20240012390A (ko) | 2021-04-21 | 2024-01-29 | 애머린 파마슈티칼스 아일랜드 리미티드 | 심부전의 위험을 감소시키는 방법 |
CN116407543A (zh) * | 2021-12-29 | 2023-07-11 | 中国科学院上海药物研究所 | Epa-ee纳米脂质组合物、及其制剂、制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007001558A (es) | 2004-08-06 | 2008-03-13 | Transform Pharmaceuticals Inc | Formulaciones novedosas de fenofibrato y metodos de tratamiento relacionados. |
JP6176894B2 (ja) * | 2009-03-09 | 2017-08-09 | プロノヴァ・バイオファーマ・ノルゲ・アーエス | 脂肪酸油混合物及び界面活性剤を含む組成物、並びにその方法及び使用 |
CA2972063C (en) * | 2009-05-22 | 2019-12-17 | Mochida Pharmaceutical Co., Ltd. | Self-emulsifying composition of .omega.3 fatty acid |
JP2011006380A (ja) * | 2009-05-22 | 2011-01-13 | Mochida Pharmaceut Co Ltd | ω3脂肪酸の乳化組成物 |
JP5421674B2 (ja) * | 2009-07-01 | 2014-02-19 | 株式会社ファンケル | ソフトカプセル用乳化組成物及びソフトカプセル剤 |
EP2488022B1 (en) * | 2009-10-16 | 2018-01-10 | Mochida Pharmaceutical Co., Ltd. | Compositions |
AR082930A1 (es) * | 2010-09-08 | 2013-01-16 | Pronova Biopharma Norge As | Composiciones que comprenden una mezcla oleosa de acidos grasos, un tensioactivo y una estatina |
JP5820256B2 (ja) | 2011-02-10 | 2015-11-24 | 株式会社ファンケル | 自己乳化製剤 |
-
2014
- 2014-07-17 EP EP14826603.4A patent/EP3023099B1/en active Active
- 2014-07-17 WO PCT/JP2014/069114 patent/WO2015008848A1/ja active Application Filing
- 2014-07-17 SG SG10201800243XA patent/SG10201800243XA/en unknown
- 2014-07-17 JP JP2015527342A patent/JPWO2015008848A1/ja active Pending
- 2014-07-17 CN CN202010690422.1A patent/CN111939125A/zh active Pending
- 2014-07-17 MY MYPI2016700151A patent/MY187003A/en unknown
- 2014-07-17 CN CN202010690704.1A patent/CN111888343A/zh active Pending
- 2014-07-17 CN CN201480040469.6A patent/CN105530927A/zh active Pending
- 2014-07-17 KR KR1020167001712A patent/KR102275447B1/ko active IP Right Grant
- 2014-07-17 SG SG11201600337PA patent/SG11201600337PA/en unknown
- 2014-07-17 CA CA2918330A patent/CA2918330C/en active Active
- 2014-07-17 US US14/905,652 patent/US20160158184A1/en not_active Abandoned
- 2014-07-17 CN CN201911271882.4A patent/CN110840874A/zh active Pending
- 2014-07-17 EP EP20190189.9A patent/EP3763364A1/en active Pending
- 2014-07-17 ES ES14826603T patent/ES2841344T3/es active Active
-
2016
- 2016-01-15 PH PH12016500100A patent/PH12016500100B1/en unknown
- 2016-09-09 HK HK16110704.8A patent/HK1222551A1/zh unknown
-
2019
- 2019-08-08 JP JP2019146152A patent/JP2020011958A/ja active Pending
-
2021
- 2021-01-06 US US17/142,558 patent/US20210128510A1/en active Pending
-
2022
- 2022-02-01 JP JP2022013981A patent/JP2022062147A/ja active Pending
-
2023
- 2023-12-04 JP JP2023204610A patent/JP2024028839A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2015008848A1 (ja) | 2015-01-22 |
KR102275447B1 (ko) | 2021-07-08 |
EP3023099A1 (en) | 2016-05-25 |
US20160158184A1 (en) | 2016-06-09 |
CA2918330A1 (en) | 2015-01-22 |
EP3763364A1 (en) | 2021-01-13 |
JP2024028839A (ja) | 2024-03-05 |
PH12016500100A1 (en) | 2016-04-18 |
CN105530927A (zh) | 2016-04-27 |
JP2022062147A (ja) | 2022-04-19 |
US20210128510A1 (en) | 2021-05-06 |
ES2841344T3 (es) | 2021-07-08 |
SG10201800243XA (en) | 2018-02-27 |
JP2020011958A (ja) | 2020-01-23 |
KR20160032120A (ko) | 2016-03-23 |
CA2918330C (en) | 2022-08-30 |
PH12016500100B1 (en) | 2016-04-18 |
EP3023099B1 (en) | 2020-09-30 |
CN111939125A (zh) | 2020-11-17 |
EP3023099A4 (en) | 2017-01-04 |
CN111888343A (zh) | 2020-11-06 |
MY187003A (en) | 2021-08-26 |
CN110840874A (zh) | 2020-02-28 |
JPWO2015008848A1 (ja) | 2017-03-02 |
HK1222551A1 (zh) | 2017-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201600337PA (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID | |
HK1243324A1 (zh) | ω3脂肪酸的自乳化組合物 | |
EP3735963C0 (en) | SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACIDS | |
IL249821A0 (en) | Preparations of omega 3 fatty acid esters | |
IL269227B (en) | Solid forms of treprostinil | |
EP2861227A4 (en) | OMEGA-3 PENTAIC ACID COMPOSITIONS AND METHODS OF USE | |
HK1206248A1 (zh) | 他汀類藥物和ω- 脂肪酸的組合物 | |
EP3248599A4 (en) | Omega-3 fatty acid self-emulsifying composition | |
EP3056090A4 (en) | Oil/fat composition containing polyunsaturated fatty acid | |
SI2984490T1 (sl) | Metode proizvodnje derivatov omega hidroksilirane maščobne kisline | |
EP2961729A4 (en) | PREPARATION OF BIOPOLYL ESTERS FOR LUBRICANTS APPLICATION | |
PL2997117T3 (pl) | Zastosowanie estru | |
EP2827868A4 (en) | PHARMACEUTICAL COMPOSITIONS COMPRISING FATTY ACID ESTERS | |
EP3069615A4 (en) | Fat containing polyunsaturated fatty acid | |
PL2996484T3 (pl) | Zastosowanie kwasu tłuszczowego z oleju talowego | |
IL279291A (en) | Morphic forms of hexadecyloxypropyl-phosphonate esters | |
PL2860211T3 (pl) | Preparaty estrów kwasu fosforowego o obniżonej higroskopijności | |
EP2849578A4 (en) | USE OF DISPOSED TALL OIL FATTY ACID | |
EP2968246A4 (en) | OMEGA 3 PENTANOIC ACID COMPOSITIONS AND METHODS OF USE | |
IL245588A0 (en) | Solid compositions of triglycerides and their use | |
EP2929041A4 (en) | PENTAENOIC ACID COMPOSITIONS OF OMEGA-3 AND ASSOCIATED METHODS OF USE | |
EP2845585A4 (en) | COMPOSITION OF FATTY ACID ESTERS OF TRHEHALOSIS | |
HRP20182110T1 (hr) | Sastav spojeva tiakumicina | |
EP2964772A4 (en) | PREPARATION OF OMEGA-3 FATTY ACIDS FROM PYTHIUM SPECIES | |
SG10202103821WA (en) | SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID |